What the research found

Life Biosciences has released interim safety data from the first three participants in a Phase 1 trial of ER-100, a gene therapy delivered via injection into the eye. The treatment works by expressing three transcription factors (OCT4, SOX2, KLF4) to attempt "resetting" retinal cells to a younger state. Participants received a single injection plus eight weeks of daily doxycycline to activate the gene expression, alongside a steroid taper to manage inflammation.

Through 56 days, the therapy showed no serious adverse events or dose-limiting toxicities. The adverse effects observed were attributed to the injection procedure itself, the steroid, or pre-existing conditions—not the therapy. More notably, two of the three participants showed measurable improvement in visual field testing (Humphrey Visual Fields), with over a quarter of their tested visual points improving by more than 4 dB. The trial safety board recommended proceeding to a higher dose level.

Why it matters for you

If you're tracking aging biomarkers, this represents a direct attempt at epigenetic rejuvenation in living humans—moving beyond animal models. The mechanism (OSK transcription factors) is grounded in cellular reprogramming research, which aligns with the broader science underpinning longevity protocols. However, this is strictly ophthalmology-focused; it won't improve your general health markers or systemic aging.

The timeline and intervention pattern may interest those exploring senolytic or epigenetic approaches: a single intervention plus a defined pharmacological window (doxycycline induction over 8 weeks) offers a cleaner mechanistic picture than most supplement stacks. That said, this is not yet available outside trials, carries surgical risk, and addresses a specific disease (glaucoma) rather than healthy aging or performance.

Caveats

• Extremely early stage: Phase 1 with n=3 participants; primarily evaluates safety, not efficacy
• Open-label design: No control group or blinding; visual improvements could reflect placebo effect, natural variation, or measurement noise
• Short follow-up: 56 days is brief; long-term safety and durability unknown
• Company-sponsored: Announced by the manufacturer; independent verification pending
• Invasive: Requires intravitreal injection, which carries infection and detachment risk
• Limited generalisability: Glaucoma-specific; unclear if mechanism would translate to other tissues or systemic aging